Blackrock, INC Schedule 13G passive stakes

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.0% beneficial ownership stake in Cooper Standard Holdings Inc. as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, confirming its beneficial ownership of 8.9% of Crown Castle Inc.'s common stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reaffirming its significant 9.0% beneficial ownership stake in D.R. Horton, Inc. common stock as of March 31, 2025.

BlackRock, Inc. has filed an updated Schedule 13G, revealing a 9.1% beneficial ownership stake in Dynex Capital Inc.'s common stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 5.8% passive beneficial ownership stake in Dyne Therapeutics, Inc. as of March 31, 2025.

BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting a 7.9% beneficial ownership stake in Editas Medicine, Inc. as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.8% beneficial ownership stake in Enanta Pharmaceuticals Inc. as of March 31, 2025, indicating a passive investment.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 9.2% beneficial ownership stake in Envista Holdings Corp., held for passive investment purposes.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 16.9% of the common stock of Essential Properties Realty Trust, Inc. as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.0% beneficial ownership stake in EVgo Inc.'s common stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, revealing its beneficial ownership of 6.8% of FrontView REIT, Inc.'s common stock as of March 31, 2025.

BlackRock, Inc. has filed an updated Schedule 13G, reaffirming its substantial passive ownership of 7.5% of Guardant Health, Inc.'s common stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.3% beneficial ownership stake in McKesson Corporation as of March 31, 2025, held for ordinary course of business.

BlackRock, Inc. has filed an Amendment No. 5 to its Schedule 13G, reporting a 7.8% beneficial ownership stake in AMC Networks Inc.'s Class A Stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reaffirming its significant passive stake in AECOM, holding 9.8% of the common stock as of March 31, 2025.

BlackRock, Inc. has filed an Amendment No. 2 to its Schedule 13G, disclosing a continued passive beneficial ownership of 5.9% in Alpine Income Property Trust, Inc. as of March 31, 2025.

BlackRock, Inc. has disclosed an increased passive ownership stake in Arvinas, Inc., now holding 7.9% of the company's common stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 7.5% of Avidity Biosciences Inc.'s common stock as of March 31, 2025.

BlackRock, Inc. has filed an Amendment No. 3 to Schedule 13G, reporting a beneficial ownership of 8.5% of Baker Hughes Co's Class A Stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 8.4% of BioCryst Pharmaceuticals Inc.'s common stock as of March 31, 2025.

BlackRock, Inc. has filed an Amendment No. 7 to Schedule 13G, reporting a 7.4% beneficial ownership stake in Cannae Holdings Inc. as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, confirming its continued beneficial ownership of 8.0% of CareDx Inc.'s common stock as of March 31, 2025.

BlackRock, Inc. has filed an Amendment No. 4 to its Schedule 13G, revealing a 7.3% beneficial ownership stake in Celldex Therapeutics, Inc. as of March 31, 2025.

BlackRock, Inc. has filed an Amendment No. 13 to its Schedule 13G, disclosing a 9.2% beneficial ownership stake in Chimera Investment Corporation as of March 31, 2025.

BlackRock, Inc. has filed an Amendment No. 7 to its Schedule 13G, reporting a 16.6% beneficial ownership stake in Easterly Government Properties Inc. as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 9.0% passive beneficial ownership stake in Enphase Energy Inc. as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.2% beneficial ownership stake in Evolution Petroleum Corporation's common stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 7.4% of the common stock of Fidelity National Information Services Inc. as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 7.8% of 4D Molecular Therapeutics Inc.'s Common Stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.6% beneficial ownership stake in ACM Research, Inc.'s Class A Stock as of March 31, 2025.